Denver—In chronic myelogenous leukemia (CML) patients taking a tyrosine kinase inhibitor (TKI), earlier initiation of molecular testing is associated with lower treatment costs and less likelihood of disease progression, according to a case-control study. Early and frequent molecular monitoring is recommended in the National Comprehensive Cancer Network (NCCN) guidelines, but there are data suggesting that many patients are not monitored appropriately.
“Earlier monitoring may have